invopressin (OCE-205) / Ocelot Bio - LARVOL DELTA

OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial. (PubMed, Hepatology) - "OCE-205 was well tolerated, with no evidence of excessive vasoconstriction or related events of ischemia or respiratory failure at any dose level. OCE-205 had a predictable, capped maximal efficacy that improved HRS-AKI in numerically more patients than placebo, though was underpowered for statistical significance. OCE-205 warrants additional investigation as a novel HRS therapy with a favorable benefit/risk profile."

Clinical • Journal • P2 data • Acute Kidney Injury • Cardiovascular • Fibrosis • Hepatology • Immunology • Liver Failure • Nephrology • Renal Disease • Respiratory Diseases